Bellerophon Therapeutics Inc.

4.46-0.0100-0.22%Vol 58.28K1Y Perf -64.94%
Apr 16th, 2021 16:00 DELAYED
BID4.43 ASK4.95
Open4.50 Previous Close4.47
Pre-Market- After-Market4.46
 - -  - -%
Target Price
23.67 
Analyst Rating
Strong Buy 1.00
Potential %
430.72 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap42.40M 
Earnings Rating
Neutral
Price Range Ratio 52W %
1.18 
Earnings Date
10th May 2021

Today's Price Range

4.364.51

52W Range

4.2621.28

5 Year PE Ratio Range

-11.70-1.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-8.42%
1 Month
-34.60%
3 Months
-41.01%
6 Months
-51.84%
1 Year
-64.94%
3 Years
-85.57%
5 Years
-86.55%
10 Years
-

TickerPriceChg.Chg.%
BLPH4.46-0.0100-0.22
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.84-
Q03 2020-0.82-0.84-2.44
Q02 2020-0.68-0.5125.00
Q01 2020-1.02-0.8912.75
Q03 2019-1.20-0.9025.00
Q02 2019-1.05-0.9014.29
Q01 2019-0.15-
Q04 2018-1.80-0.3083.33
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.7169.66Positive
6/2021 QR-0.6963.30Positive
12/2021 FY-2.75--
12/2022 FY-2.31--
Next Report Date10th May 2021
Estimated EPS Next Report-0.71
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume58.28K
Shares Outstanding9.51M
Trades Count645
Dollar Volume599.54K
Avg. Volume78.41K
Avg. Weekly Volume59.63K
Avg. Monthly Volume93.00K
Avg. Quarterly Volume81.67K

Bellerophon Therapeutics Inc. (NASDAQ: BLPH) stock closed at 4.46 per share at the end of the most recent trading day (a -0.22% change compared to the prior day closing price) with a volume of 58.50K shares and market capitalization of 42.40M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Bellerophon Therapeutics Inc. CEO is Fabian Tenenbaum.

The one-year performance of Bellerophon Therapeutics Inc. stock is -64.94%, while year-to-date (YTD) performance is -33.13%. BLPH stock has a five-year performance of -86.55%. Its 52-week range is between 4.26 and 21.28, which gives BLPH stock a 52-week price range ratio of 1.18%

Bellerophon Therapeutics Inc. currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 1.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -76.66%, a ROC of -72.33% and a ROE of -117.31%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Bellerophon Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.71 for the next earnings report. Bellerophon Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Bellerophon Therapeutics Inc. is Strong Buy (1), with a target price of $23.67, which is +430.72% compared to the current price. The earnings rating for Bellerophon Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bellerophon Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bellerophon Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.68, ATR14 : 0.45, CCI20 : -117.57, Chaikin Money Flow : -0.03, MACD : -0.76, Money Flow Index : 18.04, ROC : -13.90, RSI : 36.45, STOCH (14,3) : 14.08, STOCH RSI : 0.50, UO : 37.50, Williams %R : -85.92), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bellerophon Therapeutics Inc. in the last 12-months were: Theodore Wang (Buy at a value of $96 896), Wassim Fares (Buy at a value of $40 708)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension.

CEO: Fabian Tenenbaum

Telephone: +1 908 574-4770

Address: 184 Liberty Corner Road, Warren 07059, NJ, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

72%28%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News

Stocktwits